A double-blind comparison of diclofenac sodium (Voltarol) and placebo in inpatients with rheumatoid arthritis.
This preliminary study compared placebo with diclofenac (50 mg, rising to 150 mg per day) in a crossover study for seven days in thirteen inpatients. Regardless of the marked overall effect of hospitalization, an additional effect of diclofenac on grip strength and p.i.p. joint swelling was demonstrated, as well as a significant reduction in pain and in analgesic requirements. In addition, an improved technique for assessing the effect of NSAI drugs on p.i.p. joint swelling is described.
D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000473:pathology; D001241:Aspirin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004008:Diclofenac / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D007596:Joints / Q000473:pathology; D010648:Phenylacetates / Q000627:therapeutic use*
D010648:Phenylacetates; D004008:Diclofenac; D001241:Aspirin